Patents by Inventor Abhisek Banerjee

Abhisek Banerjee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE
    Publication number: 20240059703
    Abstract: Provided are compounds of Formula (I) having activity as inhibitors of G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and uses and methods of treating certain disorders, such as cancer, including but not limited to lung, pancreatic and colorectal cancers.
    Type: Application
    Filed: October 19, 2021
    Publication date: February 22, 2024
    Inventors: BRIAN ALAN LANMAN, ABHISEK BANERJEE, MARGARET CHU-MOYER, DONGCHENG DAI, JOSEPHINE ESHON, DAVID HUANG, MATTHEW R. KALLER, HEEJUN LEE, PATRICIA LOPEZ, VU VAN MA, FRANCESCO MANONI, JOSE M MEDINA, ALEXANDER J. PICKRELL, JOHN C. STELLWAGEN, ZHEN SUN, NURIA A. TAMAYO, WENHAN ZHANG, KAI ZHU
  • HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE
    Publication number: 20230406860
    Abstract: The present disclosure provides compounds of Formula (I) having activity as inhibitors of G12C mutant KRAS protein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses and methods of treating certain disorders, such as cancer, including but not limited to lung, pancreatic and colorectal cancers.
    Type: Application
    Filed: October 26, 2021
    Publication date: December 21, 2023
    Inventors: BRIAN ALAN LANMAN, ABHISEK BANERJEE, MARGARET CHU-MOYER, DONGCHENG DAI, MATTHEW R. KALLER, PATRICIA LOPEZ, VU VAN MA, FRANCESCO MANONI, JOSE M. MEDINA, ALEXANDER J. PICKRELL, NURIA A. TAMAYO, KAI ZHU
  • QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS
    Publication number: 20230322726
    Abstract: A compound of formula I wherein A, X, Y, Z, R1 and R24 are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, IKur-associated disorders, and other disorders mediated by ion channel function.
    Type: Application
    Filed: March 24, 2023
    Publication date: October 12, 2023
    Inventors: James A. Johnson, John Lloyd, Heather Finlay, James Neels, Naveen Kumar Dhondi, Prashantha Gunaga, Abhisek Banerjee, Ashokkumar Adisechan
  • SMARCA2-VHL DEGRADERS
    Publication number: 20230091042
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Application
    Filed: January 8, 2021
    Publication date: March 23, 2023
    Applicant: AMGEN INC.
    Inventors: Abhisek BANERJEE, Victor J. CEE, Ning CHEN, Xiaofen LI, Ryan Paul WURZ
  • N-cyano-7-azanorbornane derivatives and uses thereof
    Patent number: 11572374
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: February 7, 2023
    Assignee: AMGEN INC.
    Inventors: John R. Butler, Daniel Erlanson, Russell Graceffa, Jeffrey Iwig, Joon Won Jeong, Ryan D. White, Yongwei Wu, Shuyan Yi, Xiao Mei Zheng, Jesse M. McFarland, Abhisek Banerjee
  • KIF18A INHIBITORS
    Publication number: 20220372018
    Abstract: Amide compounds of formula (I): as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
    Type: Application
    Filed: August 3, 2020
    Publication date: November 24, 2022
    Applicant: AMGEN INC.
    Inventors: Nuria A. TAMAYO, Abhisek BANERJEE, Jian Jeffrey CHEN, Matthew Richard KALLER, Thomas T. NGUYEN, Nobuko NISHIMURA, Qiufen May XUE, John Gordon ALLEN, Michael J. FROHN
  • N-CYANO-7-AZANORBORNANE DERIVATIVES AND USES THEREOF
    Publication number: 20220363694
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Application
    Filed: August 13, 2019
    Publication date: November 17, 2022
    Applicants: Amgen Inc., Carmot Therapeutics, Inc.
    Inventors: John R. BUTLER, Daniel ERLANSON, Russell GRACEFFA, Jeffrey IWIG, Joon Won JEONG, Ryan D. WHITE, Yongwei WU, Shuyan YI, Xiao Mei ZHENG, Jesse M. MCFARLAND, Abhisek BANERJEE
  • QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS
    Publication number: 20220324836
    Abstract: A compound of formula I wherein A, X, Y, Z, R1 and R24 are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, IKur-associated disorders, and other disorders mediated by ion channel function.
    Type: Application
    Filed: April 15, 2021
    Publication date: October 13, 2022
    Inventors: James A. Johnson, John Lloyd, Heather Finlay, James Neels, Naveen Kumar Dhondi, Prashantha Gunaga, Abhisek Banerjee, Ashokkumar Adisechan
  • KIF18A INHIBITORS
    Publication number: 20220289724
    Abstract: Amide compounds of formula (I): and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of Kinesin Motor Protein KIF18A, such as cancer, psoriasis, atopic dermatitis, an autoimmune disorder, or inflammatory bowel disease, and the like.
    Type: Application
    Filed: August 3, 2020
    Publication date: September 15, 2022
    Applicant: AMGEN INC.
    Inventors: Nuria A. TAMAYO, Abhisek BANERJEE, Jian Jeffrey CHEN, Matthew Paul BOURBEAU, Matthew Richard KALLER, Jonathan Dante LOW, Ana Elena MINATTI, Thomas T. NGUYEN, Nobuko NISHIMURA, Liping H. PETTUS, Mary Catherine WALTON, Qiufen May XUE, John Gordon ALLEN
  • KIF18A INHIBITORS
    Publication number: 20220281843
    Abstract: Compounds of formula (I): (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
    Type: Application
    Filed: August 3, 2020
    Publication date: September 8, 2022
    Applicant: AMGEN INC.
    Inventors: Nuria A. TAMAYO, Abhisek BANERJEE, Matthew Paul BOURBEAU
  • KIF18A INHIBITORS
    Publication number: 20220106293
    Abstract: Compounds of formula (I): as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
    Type: Application
    Filed: December 14, 2021
    Publication date: April 7, 2022
    Applicant: AMGEN INC.
    Inventors: Nuria A. TAMAYO, Abhisek BANERJEE, James Alexander BROWN, Michael J FROHN, Jian Jeffrey CHEN, Kexue LI, Qingyian LIU, Jonathan Dante LOW, Vu MA, Liping H. PETTUS, Mary Catherine WALTON, Ana Elena MINATTI, Matthew Paul BOURBEAU, Lei JIA
  • KIF18A INHIBITORS
    Publication number: 20220073504
    Abstract: Compounds of formula (I): (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
    Type: Application
    Filed: December 20, 2019
    Publication date: March 10, 2022
    Applicant: AMGEN INC.
    Inventors: NURIA A TAMAYO, ABHISEK BANERJEE, JAMES ALEXANDER BROWN, MICHAEL J FROHN, JIAN JEFFREY CHEN, KEXUE LI, QINGYIAN LIU, JONATHAN DANTE LOW, VU MA, LIPING H PETTUS, MARY CATHERINE WALTON, ANA ELENA MINATTI, MATTHEW PAUL BOURBEAU, LEI JIA, THOMAS T NGUYEN, NOBUKO NISHIMURA, QIUFEN MAY XUE, JOHN GORDON ALLEN
  • KIF18A INHIBITORS
    Publication number: 20220056015
    Abstract: The present invention relates to chemical compounds having a general formula (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
    Type: Application
    Filed: December 20, 2019
    Publication date: February 24, 2022
    Applicant: AMGEN INC.
    Inventors: NURIA A TAMAYO, ABHISEK BANERJEE, JIAN JEFFREY CHEN, KEXUE LI, LIPING H. PETTUS, MATTHEW PAUL BOURBEAU, LEI JIA
  • KIF18A inhibitors
    Patent number: 11236069
    Abstract: Compounds of formula (I): as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: February 1, 2022
    Assignee: AMGEN INC.
    Inventors: Nuria A. Tamayo, Abhisek Banerjee, Jian Jeffrey Chen, Jonathan Dante Low, Ana Elena Minatti, Matthew Paul Bourbeau
  • KIF18A INHIBITORS
    Publication number: 20220002311
    Abstract: The present invention relates to chemical compounds having a general formula (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
    Type: Application
    Filed: December 20, 2019
    Publication date: January 6, 2022
    Applicant: AMGEN INC.
    Inventors: NURIA A TAMAYO, ABHISEK BANERJEE, MICHAEL J FROHN, JIAN JEFFREY CHEN, KEXUE LI, MATTHEW PAUL BOURBEAU, LEI JIA, MATTHEW RICHARD KALLER, THOMAS T NGUYEN, NOBUKO NISHIMURA, QIUFEN MAY XUE, JOHN GORDON ALLEN
  • Quinazolines as potassium ion channel inhibitors
    Patent number: 11008306
    Abstract: A compound of formula I wherein A, X, Y, Z, R1 and R24 are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, IKur-associated disorders, and other disorders mediated by ion channel function.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: May 18, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: James A. Johnson, John Lloyd, Heather Finlay, James Neels, Naveen Kumar Dhondi, Prashantha Gunaga, Abhisek Banerjee, Ashokkumar Adisechan
  • QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS
    Publication number: 20200255407
    Abstract: A compound of formula I wherein A, X, Y, Z, R1 and R24 are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, IKur-associated disorders, and other disorders mediated by ion channel function.
    Type: Application
    Filed: May 1, 2020
    Publication date: August 13, 2020
    Inventors: James A. Johnson, John Lloyd, Heather Finlay, James Neels, Naveen Kumar Dhondi, Prashantha Gunaga, Abhisek Banerjee, Ashokkumar Adisechan
  • KIF18A INHIBITORS
    Publication number: 20200239441
    Abstract: Compounds of formula (I): as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
    Type: Application
    Filed: December 20, 2019
    Publication date: July 30, 2020
    Applicant: AMGEN INC.
    Inventors: Nuria A. TAMAYO, Abhisek BANERJEE, James Alexander BROWN, Michael J. FROHN, Jian Jeffrey CHEN, Kexue LI, Qingyian LIU, Jonathan Dante LOW, Vu MA, Liping H. PETTUS, Mary Catherine WALTON, Ana Elena MINATTI, Matthew Paul BOURBEAU, Lei JIA
  • Quinazolines as potassium ion channel inhibitors
    Patent number: 10676460
    Abstract: A compound of formula I wherein A, X, Y, Z, R1 and R24 are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, IKur-associated disorders, and other disorders mediated by ion channel function.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: June 9, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: James A. Johnson, John Lloyd, Heather Finlay, James Neels, Naveen Kumar Dhondi, Prashantha Gunaga, Abhisek Banerjee, Ashokkumar Adisechan
  • QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS
    Publication number: 20190144426
    Abstract: A compound of formula I wherein A, X, Y, Z, R1 and R24 are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, IKur-associated disorders, and other disorders mediated by ion channel function.
    Type: Application
    Filed: January 9, 2019
    Publication date: May 16, 2019
    Inventors: James A. Johnson, John Lloyd, Heather Finlay, James Neels, Naveen Kumar Dhondi, Prashantha Gunaga, Abhisek Banerjee, Ashokkumar Adisechan